1.Andersson R., Gebhard C., Miguel-Escalada I., Hoof I., Bornholdt J., Boyd M., Chen Y., Zhao X., Schmidl C. and Suzuki T. (2014) An atlas of active enhancers across human cell types and tissues. Nature 507:455-461.
2.Benetatos L., Hatzimichael E., Dasoula A., Dranitsaris G., Tsiara S., Syrrou M., Georgiou I. and Bourantas K. L. (2010) CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leukemia research 34:148-153.
3.Benetatos L., Vartholomatos G. and Hatzimichael E. (2011) MEG3 imprinted gene contribution in tumorigenesis. International Journal of Cancer 129:773-779.
4.Birney E., Stamatoyannopoulos J. A., Dutta A., Guigo R., Gingeras T. R., Margulies E. H., Weng Z., Snyder M., Dermitzakis E. T. and Thurman R. E. (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447:799-816.
5.Braconi C., Kogure T., Valeri N., Huang N., Nuovo G., Costinean S., Negrini M., Miotto E., Croce C. and Patel T. (2011) microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 30:4750-4756.
6.Calin G. A. and Croce C. M. (2006) MicroRNA signatures in human cancers. Nature Reviews Cancer 6:857-866.
7.Carninci P., Kasukawa T., Katayama S., Gough J., Frith M., Maeda N., Oyama R., Ravasi T., Lenhard B. and Wells C. (2005) The transcriptional landscape of the mammalian genome. Science 309:1559-1563.
8.Cathcart P., Lucchesi W., Ottaviani S., De Giorgio A., Krell J., Stebbing J. and Castellano L. (2015) Noncoding RNAs and the control of signalling via nuclear receptor regulation in health and disease. Best Practice & Research Clinical Endocrinology & Metabolism 29:529-543.
9.Choudhry H., Albukhari A., Morotti M., Haider S., Moralli D., Smythies J., Schödel J., Green C., Camps C. and Buffa F. (2015) Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival. Oncogene 34:4482-4490.
10.Clemson C. M., Hutchinson J. N., Sara S. A., Ensminger A. W., Fox A. H., Chess A. and Lawrence J. B. (2009) An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Molecular cell 33:717-726.
11.Consortium E. P. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489:57-74.
12.DeOcesano-Pereira C., Amaral M. S., Parreira K. S., Ayupe A. C., Jacysyn J. F., Amarante-Mendes G. P., Reis E. M. and Verjovski-Almeida S. (2014) Long non-coding RNA INXS is a critical mediator of BCL-XS induced apoptosis. Nucleic acids research 42:8343-8355.
13.Dimitrova N., Zamudio J. R., Jong R. M., Soukup D., Resnick R., Sarma K., Ward A. J., Raj A., Lee J. T. and Sharp P. A. (2014) LincRNA-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint. Molecular cell 54:777-790.
14.El‐Kenawi A. E. and El‐Remessy A. B. (2013) Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. British journal of pharmacology 170:712-729.
15.Fatemi R. P., Velmeshev D. and Faghihi M. A. (2014) De-repressing LncRNA-targeted genes to upregulate gene expression: focus on small molecule therapeutics. Molecular Therapy—Nucleic Acids 3:e196.
16.Fu W.-m., Lu Y.-f., Hu B.-g., Liang W.-c., Zhu X., Yang H.-d., Li G. and Zhang J.-f. (2016) Long noncoding RNA hotair mediated angiogenesis in nasopharyngeal carcinoma by direct and indirect signaling pathways. Oncotarget 7:4712.
17.Gibb E. A., Brown C. J. and Lam W. L. (2011) The functional role of long non-coding RNA in human carcinomas. Molecular cancer 10:1.
18.Gutschner T. and Diederichs S. (2012) The hallmarks of cancer: a long non-coding RNA point of view. RNA biology 9:703-719.
19.Guttman M., Amit I., Garber M., French C., Lin M. F., Feldser D., Huarte M., Zuk O., Carey B. W. and Cassady J. P. (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458:223-227.
20.Guttman M., Donaghey J., Carey B. W., Garber M., Grenier J. K., Munson G., Young G., Lucas A. B., Ach R. and Bruhn L. (2011) lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 477:295-300.
21.Halford C. (2013) Preliminary investigation of the effects of silencing the non-coding RNA, NEAT1, on the Burkitt's lymphoma cell line BJAB. Bioscience Horizons 6: hzt006.
22.Hanahan D. and Weinberg R. A. (2000) The hallmarks of cancer. cell 100:57-70.
23.Hassan M., Watari H., AbuAlmaaty A., Ohba Y. and Sakuragi N. (2014) Apoptosis and molecular targeting therapy in cancer. BioMed research international 2014.
24.Higashimoto K., Soejima H., Saito T., Okumura K. and Mukai T. (2006) Imprinting disruption of the CDKN1C/KCNQ1OT1 domain: the molecular mechanisms causing Beckwith-Wiedemann syndrome and cancer. Cytogenetic and genome research 113:306-312.
25.Huarte M. and Rinn J. L. (2010) Large non-coding RNAs: missing links in cancer? Human molecular genetics 19:R152-R161.
26.Iacobucci I., Sazzini M., Garagnani P., Ferrari A., Boattini A., Lonetti A., Papayannidis C., Mantovani V., Marasco E. and Ottaviani E. (2011) A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. Leukemia research 35:1052-1059.
27. Imai K. and Takaoka A. (2006) Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer 6:714-727.
28.Kapranov P., Cheng J., Dike S., Nix D. A., Duttagupta R., Willingham A. T., Stadler P. F., Hertel J., Hackermüller J. and Hofacker I. L. (2007) RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 316:1484-1488.
29.Khalil A. M., Guttman M., Huarte M., Garber M., Raj A., Morales D. R., Thomas K., Presser A., Bernstein B. E. and van Oudenaarden A. (2009) Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proceedings of the National Academy of Sciences 106:11667-11672.
30.Kino T., Hurt D. E., Ichijo T., Nader N. and Chrousos G. P. (2010) Noncoding RNA Gas5 is a growth arrest and starvation-associated repressor of the glucocorticoid receptor. Science signaling 3:ra8.
31.Kitagawa M., Kitagawa K., Kotake Y., Niida H. and Ohhata T. (2013) Cell cycle regulation by long non-coding RNAs. Cellular and molecular life sciences 70:4785-4794.
32.Kotake Y., Nakagawa T., Kitagawa K., Suzuki S., Liu N., Kitagawa M. and Xiong Y. (2011) Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15INK4B tumor suppressor gene. Oncogene 30:1956-1962.
33.Kyi C. and Postow M. A. (2014) Checkpoint blocking antibodies in cancer immunotherapy. FEBS letters 588:368-376.
34.Lin S. and Gregory R. I. (2015) MicroRNA biogenesis pathways in cancer. Nature Reviews Cancer 15:321-333.
35.Liu Y., Pan S., Liu L., Zhai X., Liu J., Wen J., Zhang Y., Chen J., Shen H. and Hu Z. (2012) A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. PloS one 7:e35145.
36.Lu K.-h., Li W., Liu X.-h., Sun M., Zhang M.-l., Wu W.-q., Xie W.-p. and Hou Y.-y. (2013) Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC cancer 13:461.
37.Matouk I. J., Abbasi I., Hochberg A., Galun E., Dweik H. and Akkawi M. (2009) Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. European journal of gastroenterology & hepatology 21:688-692.
38.Mohammad F., Pandey R. R., Nagano T., Chakalova L., Mondal T., Fraser P. and Kanduri C. (2008) Kcnq1ot1/Lit1 noncoding RNA mediates transcriptional silencing by targeting to the perinucleolar region. Molecular and cellular biology 28:3713-3728.
39.Mourtada-Maarabouni M., Hasan A. M., Farzaneh F. and Williams G. T. (2010) Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5). Molecular pharmacology 78:19-28.
40.Mourtada-Maarabouni M., Hedge V. L., Kirkham L., Farzaneh F. and Williams G. T. (2008) Growth arrest in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 (GAS5). Journal of cell science 121:939-946.
41.Mourtada-Maarabouni M., Pickard M., Hedge V., Farzaneh F. and Williams G. (2009) GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 28:195-208.
42.Naganuma T. and Hirose T. (2013) Paraspeckle formation during the biogenesis of long non-coding RNAs. RNA biology 10:456-461.
43.Nakano S., Murakami K., Meguro M., Soejima H., Higashimoto K., Urano T., Kugoh H., Mukai T., Ikeguchi M. and Oshimura M. (2006) Expression profile of LIT1/KCNQ1OT1 and epigenetic status at the KvDMR1 in colorectal cancers. Cancer science 97:1147-1154.
44.Pandey R. R., Mondal T., Mohammad F., Enroth S., Redrup L., Komorowski J., Nagano T., Mancini-DiNardo D. and Kanduri C. (2008) Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Molecular cell 32:232-246.
45.Panzitt K., Tschernatsch M. M., Guelly C., Moustafa T., Stradner M., Strohmaier H. M., Buck C. R., Denk H., Schroeder R. and Trauner M. (2007) Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132:330-342.
46.Pickard M. R. and Williams G. T. (2014) Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy. Breast cancer research and treatment 145:359-370.
47.Pickl J., Heckmann D., Ratz L., Klauck S. M. and Sültmann H. (2014) Novel RNA markers in prostate cancer: functional considerations and clinical translation. BioMed research international 2014.
48.Popov N. and Gil J. (2010) Epigenetic regulation of the INK4b-ARF-INK4a locus: in sickness and in health. Epigenetics 5:685-690.
49.Prensner J. R., Chen W., Iyer M. K., Cao Q., Ma T., Han S., Sahu A., Malik R., Wilder-Romans K. and Navone N. (2014) PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer research 74:1651-1660.
50.Prensner J. R., Iyer M. K., Balbin O. A., Dhanasekaran S. M., Cao Q., Brenner J. C., Laxman B., Asangani I. A., Grasso C. S. and Kominsky H. D. (2011) Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nature biotechnology 29:742-749.
51.Puvvula P. K., Desetty R. D., Pineau P., Marchio A., Moon A., Dejean A. and Bischof O. (2014) Long noncoding RNA PANDA and scaffold-attachment-factor SAFA control senescence entry and exit. Nature communications 5.
52.Qi P. and Du X. (2013) The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Modern Pathology 26:155-165.
53.Raveh E., Matouk I. J., Gilon M. and Hochberg A. (2015) The H19 Long non-coding RNA in cancer initiation, progression and metastasis–a proposed unifying theory. Molecular cancer 14:1.
54.Rosa A. L., Wu Y.-Q., Kwabi-Addo B., Coveler K. J., Sutton V. R. and Shaffer L. G. (2005) Allele-specific methylation of a functional CTCF binding site upstream of MEG3 in the human imprinted domain of 14q32. Chromosome Research 13:809-818.
55.Rossi M. N. and Antonangeli F. (2014) LncRNAs: new players in apoptosis control. International journal of cell biology 2014.
56.Sanchez Y. and Huarte M. (2013) Long non-coding RNAs: challenges for diagnosis and therapies. Nucleic acid therapeutics 23:15-20.
57.Steeg P. S. (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nature Reviews Cancer 3:55-63.
58.Sun M., Xia R., Jin F., Xu T., Liu Z., De W. and Liu X. (2014) Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumor Biology 35:1065-1073.
59.Sunwoo H., Dinger M. E., Wilusz J. E., Amaral P. P., Mattick J. S. and Spector D. L. (2009) MEN ε/β nuclear-retained non-coding RNAs are up-regulated upon muscle differentiation and are essential components of paraspeckles. Genome research.
60.Sweeney C. J., Chen Y.-H., Carducci M., Liu G., Jarrard D. F., Eisenberger M., Wong Y.-N., Hahn N., Kohli M. and Cooney M. M. (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New England Journal of Medicine 373:737-746.
61.Takahashi H. and Carninci P. (2014) Widespread genome transcription: new possibilities for RNA therapies. Biochemical and biophysical research communications 452:294-301.
62.Tannock I. F. (1998) Conventional cancer therapy: promise broken or promise delayed? The Lancet 351:SII9-SII16.
63.Tong Y.-K. and Lo Y. D. (2006) Diagnostic developments involving cell-free (circulating) nucleic acids. Clinica Chimica Acta 363:187-196.
64.Tsai M.-C., Spitale R. C. and Chang H. Y. (2011) Long intergenic noncoding RNAs: new links in cancer progression. Cancer research 71:3-7.
65.Wan J., Huang M., Zhao H., Wang C., Zhao X., Jiang X., Bian S., He Y. and Gao Y. (2013) A novel tetranucleotide repeat polymorphism within KCNQ1OT1 confers risk for hepatocellular carcinoma. DNA and cell biology 32:628-634.
66.Wang J., Liu X., Wu H., Ni P., Gu Z., Qiao Y., Chen N., Sun F. and Fan Q. (2010) CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic acids research 38:5366-5383.
67.Weksberg R., Shuman C., Caluseriu O., Smith A. C., Fei Y.-L., Nishikawa J., Stockley T. L., Best L., Chitayat D. and Olney A. (2002) Discordant KCNQ1OT1 imprinting in sets of monozygotic twins discordant for Beckwith–Wiedemann syndrome. Human Molecular Genetics 11:1317-1325.
68.Wijnen M., Alders M., Zwaan C. M., Wagner A. and van den Heuvel‐Eibrink M. M. (2012) KCNQ1OT1 hypomethylation: a novel disguised genetic predisposition in sporadic pediatric adrenocortical tumors? Pediatric blood & cancer 59:565-566.
69.Xie H., Ma H. and Zhou D. (2013) Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. BioMed research international 2013.
70.Yan J., Guo X., Xia J., Shan T., Gu C., Liang Z., Zhao W. and Jin S. (2014) MiR-148a regulates MEG3 in gastric cancer by targeting DNA methyltransferase 1. Medical Oncology 31:1-7.
71.Yang M.-H., Hu Z.-Y., Xu C., Xie L.-Y., Wang X.-Y., Chen S.-Y. and Li Z.-G. (2015) MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1852:166-174.
72.Yap K. L., Li S., Muñoz-Cabello A. M., Raguz S., Zeng L., Mujtaba S., Gil J., Walsh M. J. and Zhou M.-M. (2010) Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Molecular cell 38:662-674.
73.Yin D.-d., Liu Z.-j., Zhang E., Kong R., Zhang Z.-h. and Guo R.-h. (2015) Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumor Biology 36:4851-4859.
74.Yu W., Gius D., Onyango P., Muldoon-Jacobs K., Karp J., Feinberg A. P. and Cui H. (2008) Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 451:202-206.
75.Zeng C., Xu Y., Xu L., Yu X., Cheng J., Yang L., Chen S. and Li Y. (2014) Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells. BMC cancer 14:1.
76.Zhang X., Gejman R., Mahta A., Zhong Y., Rice K. A., Zhou Y., Cheunsuchon P., Louis D. N. and Klibanski A. (2010) Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer research 70:2350-2358.
77.Zhang Z., Zhu Z., Watabe K., Zhang X., Bai C., Xu M., Wu F. and Mo Y. (2013) Negative regulation of lncRNA GAS5 by miR-21. Cell Death & Differentiation 20:1558-1568.
78.Zhao J., Dahle D., Zhou Y., Zhang X. and Klibanski A. (2005) Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. The Journal of Clinical Endocrinology & Metabolism 90:2179-2186.
79.Zhou Q., Chen J., Feng J. and Wang J. (2016) Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumor Biology 37:3105-3113.
80.Zhou Y., Zhong Y., Wang Y., Zhang X., Batista D. L., Gejman R., Ansell P. J., Zhao J., Weng C. and Klibanski A. (2007) Activation of p53 by MEG3 non-coding RNA. Journal of Biological Chemistry 282:24731-24742.
